March 1, 2023Open Access

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. (Funded by the National Cancer Institute and Merck Sharp and Dohme; S1801 ClinicalTrials.gov number, NCT03698019.).

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Patel et al. (Wed,) studied this question.

synapsesocial.com/papers/69d7217bef370a38abf50cc0 https://doi.org/https://doi.org/10.1056/nejmoa2211437

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer2009 · 173 citations
2Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials2017 · 1,133 citations
3Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer2003 · 2,647 citations
4PD-1 blockade induces responses by inhibiting adaptive immune resistance2014 · 6,635 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo